Dimension Therapeutics, Inc.
Dimension Therapeutics, Inc. (DMTX): 7 pipeline candidates · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.0 months
D/E 1.46 · 0% dilution
Lead: Preclinical
7 candidates
N/A
N/A
A transparent, data-derived signal for Dimension Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$14.5M
Quarterly Burn
$13.4M
Runway
8.0 mo
Revenue
$4.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Frequently asked questions
How many drug candidates are in Dimension Therapeutics, Inc.'s pipeline?
Dimension Therapeutics, Inc. (DMTX) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Dimension Therapeutics, Inc.'s lead drug candidate?
Dimension Therapeutics, Inc.'s most advanced tracked candidate is dtx101 (Preclinical) for hemophilia B.
What is Dimension Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Dimension Therapeutics, Inc. has approximately 8.0 months of cash runway.
Who is the CEO of Dimension Therapeutics, Inc.?
Dimension Therapeutics is the chief executive officer of Dimension Therapeutics, Inc. (DMTX).
Get the full picture on Dimension Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.